MEZNUVA Trademark

Trademark Overview


On Monday, July 29, 2024, a trademark application was filed for MEZNUVA with the United States Patent and Trademark Office. The USPTO has given the MEZNUVA trademark a serial number of 98670993. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, July 8, 2025. This trademark is owned by Celgene Corporation. The MEZNUVA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes.
meznuva

General Information


Serial Number98670993
Word MarkMEZNUVA
Filing DateMonday, July 29, 2024
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, July 8, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 8, 2025

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, July 29, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Trademark Events


Event DateEvent Description
Monday, July 29, 2024NEW APPLICATION ENTERED
Thursday, February 13, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, February 14, 2025ASSIGNED TO EXAMINER
Wednesday, February 19, 2025NON-FINAL ACTION WRITTEN
Wednesday, February 19, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 14, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 14, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 14, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 3, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 2, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 8, 2025PUBLISHED FOR OPPOSITION
Tuesday, July 8, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 19, 2025NON-FINAL ACTION E-MAILED